INS and Parkinson disease: In a randomized, double-blinded placebo-controlled trial with the brain penetrant insulin sensitizing glucagon-like peptide 1 (GLP1)-agonist exenatide, it was shown that exenatide treatment was associated with a reduced decline in motor dysfunction in PD patients[6].